RMC-5552

mTORC1-selective bi-steric mTOR inhibitor

QW IP activity in xeno., 5552 in Ph. I for cancer

from linking of ÒrapalogÓ + mTOR inh. + opt

Nature Chemical Biology

Revolution Medicines, Redwood City, US

3. The Revolution Medicines selective mTORC1 complex inhibitor, RMC-4529, is a Òbi-stericÓ inhibitor that has a rapamycin-derived, FKBP12-recruiting allosteric mTOR inhibitor covalently linked to an active-site (orthosteric) inhibitor of…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks